AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33560442
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy with rituximab
Trial: 32371123
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy without rituximab (Control)
Trial: 34705999
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no light treatment)
Trial: 35671553
Drug: Very Low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very Low Nicotine Content (VLNC) cigarettes (0.4 mg/g nicotine)
Trial: 35671553
Drug: Normal Nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Normal Nicotine Content (NNC) cigarettes (15.8 mg nicotine/g tobacco)
Trial: 36471412
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of NIKA and EMDR
Trial: 33036645
Drug: Breast milk
RxNorm normalized name: BREAST MILK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast milk oral stimulation
Trial: 33036645
Drug: Physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological saline oral stimulation
Trial: 34166587
Drug: DR/ER-MPH (Delayed-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DR/ER-MPH (Delayed-release and extended-release methylphenidate)
Trial: 33290616
Drug: PF-06826647 (doses:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06826647 (doses: 3, 10, 30, 100, 200, 400, or 1,600 mg for SAD; 30, 100, 400, or 1,200 mg q.d. or 200 mg b.i.d. for 10 days for MAD)
Trial: 35440611
Drug: Paracetamol (Control)
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol (Control)
Trial: 32380069
Drug: Azithromycin 250
RxNorm normalized name: azithromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 250 mg or 500 mg, three times a week for 6 months
Trial: 34738518
Drug: 7-day amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7-day amoxicillin treatment
Trial: 34738518
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose (35-50 mg/kg/day)
Trial: 34738518
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose (70-90 mg/kg/day)
Trial: 34228547
Drug: 7-day treatment
RxNorm normalized name: Gyne-Lotrimin 1% 7-Day Treatment Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day treatment
Trial: 34726708
Drug: 3-day treatment
RxNorm normalized name: Gyne-Lotrimin 2% 3-Day Treatment Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day treatment
Trial: 34738518
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses and durations
Trial: 32962487
Drug: Ranibizumab plus
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab plus fufang xueshuantong capsule (cFXST)
Trial: 34535610
Drug: Topical clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical clindamycin 1% solution combined with LAight® therapy (8 bi-weekly treatments)
Trial: 34535610
Drug: Topical clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical clindamycin 1% solution only
Trial: 33802651
Drug: Ketogenic Diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketogenic Diet with Ketone Supplement (KD + KS)
Trial: 34416788
Drug: Focal laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focal laser therapy (micropulse laser or argon laser coagulation) for treating leakage points visible in fluorescein angiography (FA)
Trial: 34416788
Drug: Systemic administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic administration of mineralocorticoid receptor antagonists, carbonic anhydrase inhibitors, or non-steroidal anti-inflammatory drugs
Trial: 33207606
Drug: Beetroot powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot powder providing 200 mg nitrate
Trial: 33207606
Drug: Beetroot with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot with 0.8 g of L-arginine
Trial: 33207606
Drug: Beetroot with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot with 1.5 g of L-arginine
Trial: 33207606
Drug: Beetroot with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot with 3.0 g of L-arginine
Trial: 34587703
Drug: Preload of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preload of low-intensity-cooked yam paste (10 g) before rice meal
Trial: 33591858
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein (20/10/3 g)
Trial: 33591858
Drug: Placebo (30/3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (30/3 g)
Trial: 35085715
Drug: Inverse-planned intensity
RxNorm normalized name: Inversedine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inverse-planned intensity modulated radiation therapy
Trial: 35085715
Drug: Forward-planned intensity
RxNorm normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Forward-planned intensity modulated radiation therapy
Trial: 35234673
Drug: Nesvacumab 3
RxNorm normalized name: Nesvacumab
DrugBank: Nesvacumab (DB15330)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nesvacumab 3 mg + aflibercept 2 mg (LD combo)
Trial: 35234673
Drug: Nesvacumab 6
RxNorm normalized name: Nesvacumab
DrugBank: Nesvacumab (DB15330)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nesvacumab 6 mg + aflibercept 2 mg (HD combo)
Trial: 35234673
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept injection (IAI) 2 mg
Trial: 33197396
Drug: Standard ACLS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard ACLS treatment
Trial: 33878461
Drug: Interferon α‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon α‐2b spray
Trial: 35010877
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cocoa and red berries
Trial: 35878179
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (placebo control group)
Trial: 32668833
Drug: Interscalene brachial
RxNorm normalized name: Brachiara mutica pollen
DrugBank: Urochloa mutica pollen (DB10716)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interscalene brachial plexus block (ISB) with 15 ml of 0.5% ropivacaine
Trial: 32668833
Drug: Anterior suprascapular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anterior suprascapular nerve block (SSB) with 15 ml of 0.5% ropivacaine
Trial: 32668833
Drug: Posterior suprascapular
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posterior suprascapular nerve block (SSB) with 15 ml of 0.5% ropivacaine
Trial: 33693907
Drug: Testosterone treatment
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone treatment (injectable testosterone undecanoate)
Trial: 36027670
Drug: Femistina (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Femistina (40 mg, oral, twice daily for 20 days)
Trial: 36027670
Drug: Canephron (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canephron (3 × 5 ml taken orally three times daily for 4 weeks)
Trial: 34022636
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose of 4-factor prothrombin complex concentrate (4FPCC) at 1500 IU
Trial: 34022636
Drug: Variable dosing
RxNorm normalized name: methohexital
DrugBank: Methohexital (DB00474)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Variable dosing of 4-factor prothrombin complex concentrate (4FPCC)
Trial: 34404144
Drug: Micro-implant assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micro-implant assisted rapid palatal expansion (MARPE) in fusion group
Trial: 34404144
Drug: Micro-implant assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micro-implant assisted rapid palatal expansion (MARPE) in non-fusion group
Trial: 34285004
Drug: Antibiotics (penicillins,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (penicillins, cephalosporins, macrolides)
Trial: 32916306
Drug: Oral butyrate
RxNorm normalized name: butyrate
DrugBank: Butyric Acid (DB03568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral butyrate supplementation
Trial: 36259475
Drug: MitoQ (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MitoQ (20 mg/day, oral)
Trial: 32920164
Drug: CBT-based mobile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT-based mobile application (4 min daily exercises for two weeks)
Trial: 36174627
Drug: Adjuvant S-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant S-1 plus endocrine therapy
Trial: 34813901
Drug: Nutritional supplement
RxNorm normalized name: Nutritional supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplement (20 g whey protein + 800 IU vitamin D)
Trial: 33735416
Drug: Varenicline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline (1 mg BID for 12 weeks)
Trial: 33423990
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave therapy (ESWT) applied for 5 weeks, one session per week
Trial: 33423990
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) applied with 15 sessions on consecutive days
Trial: 34532888
Drug: Itraconazole 200
RxNorm normalized name: itraconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 200 mg/day
Trial: 35976021
Drug: Tapinarof 1%
RxNorm normalized name: TAPINAROF 1% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapinarof 1% cream applied once daily for 12 weeks
Trial: 33498159
Drug: Aggressive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive treatment at both metastatic and primary sites (Group A)
Trial: 33498159
Drug: Non-aggressive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-aggressive treatment (Group B)
Trial: 33498159
Drug: Patients not
RxNorm normalized name: Lamictal 25mg-100mg Tablet Starter Kit (For Patients Not Taking Enzyme-Inducing Drugs or Valproate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients not treated with PD-L1 inhibitors
Trial: 35266589
Drug: TXA 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA 15 mg/kg bolus dose, followed by 2 mg/kg/hr infusion over 8 hours
Trial: 35266589
Drug: TXA 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA 30 mg/kg bolus dose, followed by 4 mg/kg/hr infusion over 8 hours
Trial: 35266589
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline placebo bolus and infusion
Trial: 34040108
Drug: JNJ-61803534 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-61803534 (oral formulation)
Trial: 32009005
Drug: Trigger point
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trigger point injections
Trial: 35954850
Drug: Psychodynamic psychotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychodynamic psychotherapy treatment over 28 sessions
Trial: 33904295
Drug: Short course
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short course antibiotics (1g of ceftriaxone with 500mg of metronidazole stat post umbilical cord clamping)
Trial: 33904295
Drug: Long course
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long course antibiotics (post-operative doses of intravenous ceftriaxone 1g 12 hourly with 500mg of metronidazole eight hourly for 24 hours, then oral cefuroxime 500mg twice daily and metronidazole 400mg thrice daily for five days)
Trial: 33904295
Drug: Short course
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short course antibiotics
Trial: 33904295
Drug: Long course
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long course antibiotics
Trial: 32054483
Drug: Wharton's jelly
RxNorm normalized name: Human Umbilical Cord Wharton's Jelly-derived Mesenchymal Stem Cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wharton's jelly formulation
Trial: 34030555
Drug: BDP 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP 200 µg BID
Trial: 34030555
Drug: BDP 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP 50 µg BID
Trial: 34030555
Drug: BDP 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP 400 µg BID
Trial: 34030555
Drug: QVAR® 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QVAR® 160 µg BID
Trial: 33634478
Drug: Reduced-dose facilitated
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced-dose facilitated PCI strategy (reduced-dose fibrinolysis combined with simultaneous transfer for immediate invasive therapy with a time interval between fibrinolysis to PCI < 3 hours)
Trial: 33634478
Drug: Standard pharmacoinvasive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pharmacoinvasive treatment
Trial: 37057581
Drug: Chamomile vaginal
RxNorm normalized name: Chamomile
DrugBank: Chamomile (DB14357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chamomile vaginal gel 5%
Trial: 37057581
Drug: Placebo vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo vaginal gel
Trial: 34032739
Drug: On-demand treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-demand treatment with nonacog alfa
Trial: 34032739
Drug: Prophylactic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic treatment with nonacog alfa
Trial: 32583300
Drug: Aprepitant and
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprepitant and transdermal scopolamine preoperatively followed by ondansetron and dexamethasone intraoperatively, with total intravenous anesthesia.
Trial: 32583300
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (aprepitant and transdermal scopolamine)
Trial: 33216048
Drug: Grape vinegar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grape vinegar and rose water solution
Trial: 32227432
Drug: Empagliflozin 10
RxNorm normalized name: empagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 10 or 25 mg
Trial: 33050893
Drug: Theory of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theory of planned behavior (TPB) based oral health education consisting of four one-hour training sessions over 1 week.
Trial: 36717556
Drug: Levonorgestrel implant
RxNorm normalized name: levonorgestrel IMPLANT KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel implant (LNG)
Trial: 34801714
Drug: Tafenoquine 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafenoquine 200 mg weekly
Trial: 34097713
Drug: 0.75 mg
RxNorm normalized name: propinox 0.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg ml‐1 S‐ketamine in oxycodone PCA
Trial: 34097713
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg ml‐1 S‐ketamine in oxycodone PCA
Trial: 34097713
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg ml‐1 S‐ketamine in oxycodone PCA
Trial: 33731164
Drug: Vancomycin (powder,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (powder, 1 g) applied before water-tight closure of the joint capsule
Trial: 33067287
Drug: Stand-alone VR
RxNorm normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stand-alone VR (6-week, internet-based intervention with weekly online sessions and daily exercises)
Trial: 35830423
Drug: ZeroPhobia: Arachnophobia,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZeroPhobia: Arachnophobia, a 6‐week Augmented Reality Exposure Therapy smartphone self‐help application
Trial: 35012962
Drug: Plitidepsin 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plitidepsin 1.5 mg once daily for 3 days
Trial: 35012962
Drug: Plitidepsin 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plitidepsin 2.0 mg once daily for 3 days
Trial: 35012962
Drug: Plitidepsin 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plitidepsin 2.5 mg once daily for 3 days
Trial: 35012962
Drug: Plitidepsin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plitidepsin (all doses)
Trial: 32295593
Drug: Indacaterol/glycopyrronium/mometasone furoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indacaterol/glycopyrronium/mometasone furoate (IND/GLY/MF) high-dose ICS (160 μg mometasone furoate)
Trial: 32295593
Drug: Indacaterol/glycopyrronium/mometasone furoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indacaterol/glycopyrronium/mometasone furoate (IND/GLY/MF) medium-dose ICS (80 μg mometasone furoate)
Trial: 32295593
Drug: Salmeterol/fluticasone propionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol/fluticasone propionate (SFC) high-dose ICS (50/500 μg)
Trial: 32295593
Drug: Indacaterol/glycopyrronium/mometasone furoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indacaterol/glycopyrronium/mometasone furoate (IND/GLY/MF) high-dose ICS
Trial: 32295593
Drug: Indacaterol/glycopyrronium/mometasone furoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indacaterol/glycopyrronium/mometasone furoate (IND/GLY/MF) medium-dose ICS
Trial: 34469767
Drug: Quadpill treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadpill treatment (irbesartan 37.5 mg, amlodipine 1.25 mg, indapamide 0.625 mg, bisoprolol 2.5 mg)
Trial: 34469767
Drug: Quadpill treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadpill treatment
Trial: 34469767
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose monotherapy (irbesartan 150 mg)
Trial: 36116516
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose monotherapy
Trial: 32362238
Drug: High-intensity intervention
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity intervention (Motivational interviewing, dietary advice on prescription, grocery store lecture, website, weekly e-mails)
Trial: 35532889
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg testosterone enanthate weekly (n=24)
Trial: 33545945
Drug: Pestle needle
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pestle needle therapy applied to acupoints (bilateral Shao ze, bilateral Ru gen, Dan zhong, 8 array acupoints of Shen dao) once a day for 5 days
Trial: 34563412
Drug: Neonatal circumcision
RxNorm normalized name: Foreskin fibroblast (neonatal)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neonatal circumcision + antibiotic prophylaxis (CATB)
Trial: 34563412
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis alone (ATB)
Trial: 33804374
Drug: Traditional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional physical therapy for 30 min, three times a week for four weeks
Trial: 36288583
Drug: US-guided Erector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US-guided Erector Spinae Block (ESB) with 25 mg bupivacaine 0.5% plus 8 mg dexamethasone (10 mL volume)
Trial: 36288583
Drug: US-guided Thoracic
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US-guided Thoracic Paravertebral Block (PVB) with 25 mg bupivacaine 0.5% plus 8 mg dexamethasone (10 mL volume)
Trial: 33465277
Drug: PF-06372865 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06372865 (25 mg twice daily for 14 days after titration for 7 days)
Trial: 33465277
Drug: PF-06372865 (42.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06372865 (42.5 mg twice daily for 14 days after titration for 7 days)
Trial: 35436355
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose melatonin (5.0 mg)
Trial: 35436355
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose melatonin (0.3 mg)
Trial: 35353163
Drug: Vaginal estradiol
RxNorm normalized name: estradiol Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal estradiol (10-μg)
Trial: 34483029
Drug: Ivermectin 24
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin 24 mg